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Teaching Lecture: General introduction to head and neck 
radiotherapy  
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Teaching Lecture: e-Learning for Professionals in Radiation 
Oncology: What, Why and How?  
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Radiation Oncology is a dynamic and evolving field. 
Professionals need to find efficient and effective ways to stay 
informed of the latest developments, to collaborate and 
exchange knowledge with others, and to update or acquire 
new skills and competences.  
E-Learning is an excellent way to achieve this. E-Learning is 
defined as the use of information and communication 
technologies to enable learning and performance. It has the 
potential to help radiation oncologists around the world to 
develop their competences whenever they want, at any time; 
allowing them to tailor their learning experiences to their 
goals, preferences, and needs.  
This lecture will introduce the concept of e-Learning and its 
role for professional development in Radiation Oncology. It 
will present practical examples and strategies for young 
scientist to stay updated with recent findings and guidelines 
in the field, to develop their competences, and to find peers 
and opportunities for collaboration. 
 
Symposium with Proffered Papers: Quality beyond 
accuracy: are we failing to see the forest for the trees?  
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We will define ‘accuracy’ as delivering the desired radiation 
dose to the target whilst minimising as much dose as possible 
to the surrounding normal tissues, thus embracing the 
classical balance which must be achieved with all 
radiotherapy.  
The process begins with identifying the target, and therefore 
includes improving imaging for target volume delineation. 
Nevertheless, considerable uncertainties still exist especially 
in the personalisation of the Clinical Target Volume (CTV). 
Better conformation of dose to target shape has been a long 
term objective, beginning even in the ortho-voltage era. The 
biggest step, a revolutionary change, was the introduction of 
3D conformal RT. IMRT represents ‘ultra-conformal’ 
treatment. Use of proton and carbon ion beams represents 
further steps along this path.  
Improving accuracy also includes ensuring that today’s highly 
conformal treatment plans are actually delivered to the 
target, without missing, and not to surrounding normal 
tissues. This brings us to image guidance, which appears to 
be vital, especially with steep dose gradient IMRT plans, but 
which is difficult (perhaps impossible) to test using the 
conventional trial paradigms.  
A further concept is that the planned dose may differ from 
the accumulated delivered dose (DA), as the result of patient 
or tumour changes. Computational developments mean that 
individual patient DA can be estimated in a research setting 
using daily image guidance scans, so that clinical 
implementation will need to be addressed.  
An additional development is the use of real time imaging 
during the exposure to monitor patient or organ movement, 
using X-ray or MRI approaches.  
In terms of clinical outcomes, good evidence exists that 
better imaging improves outcomes. The introduction of 3D 
CRT, perhaps the most important step of all, has a strong 
evidence base. IMRT is also supported by strong clinical 
evidence. There is highly suggestive evidence that charged 
particle beams have a valuable role. Sadly, there is also good 
evidence that bad quality in plan preparation and delivery 
leads to worse local control and survival (TROG). Image 
guidance is a more challenging component of the 
radiotherapy chain for which to provide hard trial evidence, 
although it has a clear rationale.  
Overall, there is a definitive evidence base that better 
accuracy improves outcomes for both tumour control and 
normal tissue sparing using current technologies. Additional 
opportunities are also developing, making this is a truly 
exciting time to be working in radiation oncology. 
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Beyond the technological advances to improve radiation 
therapy, the patient can also actively participate in its care 
process and contribute to ameliorate its management. The 
patient is a key player in security and improvement care 
processes. The patient’s needs and expectations can be 
harvested through satisfaction surveys, adverse event 
declarations, records of complaints and patient committee.  
An important place in our Radiotherapy Department is given 
to harvesting and processing patient’s opinions to add value 
for it. In order to know the views of patients on the quality of 
our services and help us to improve it, we have developed a 
survey covering 6 themes. Figure 1 shows the surveys’ results 
of the last three years for the 6 themes, which are close or 
greater than the institutional goal. 
 
 
A patient committee is under construction. This committee, 
including former treated patients, will meet to discuss the 
satisfaction rates and improvement actions. 
We also collect complaints and unexpected events. These are 
declared on adverse event reports. These reports are 
investigated during Experience feedback committee (EFBC).  
Through these different channels the patient is actively 
involved in the quality processes of the Radiotherapy 
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Department. Thus, the patient becomes a key actor in the 
quality and safety of its own treatment. 
In conclusions: empowerment of the patient is essential for 
two reasons, on one hand at the individual level by 
strengthening its capacity to act on health determinants and 
on the other hand at the organizational level with continuous 
improvement of the Radiotherapy Department. Our goal is to 
strengthen the quality and safety of treatments, adjust them 
to the life project of the patient and promote a participative 
approach focused on the patient’s needs and expectations.  
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It has often been claimed and acknowledged that 
Radiotherapy (RT) as a modality to combat cancer has been 
technology driven, or even physicist driven. Higher energies, 
better accuracy, computerised delivery systems, 
improvements in imaging are all examples of this. Together 
with increased knowledge of how to combine RT with e.g. 
systemic treatments, RT has remained one of the most 
important tools in cancer therapy. The continuous 
improvements of RT has often involved complex technology, 
less intuitive to its nature than earlier technologies. It has 
been one of the most pronounced duties of the medical 
physicist to ensure that the clinical introduction of such new 
technologies has been done with the highest possible safety 
standards and that any risk associated with the new 
technology could be brought to an absolute minimum. As a 
result RT, in particular advanced RT, is a very safe modality 
compared to almost any other hospital activities. In their 
quest for the highest possible level of safety, the medical 
physicist is often left alone with high demands, ambitions but 
with limited means and lack of understanding from the 
hospital management of the recourses needed. As a 
consequence the clinical introduction of new, superior 
treatment options are delayed, months, years and sometimes 
even decades, and the patients have to be content with older 
methods, e.g. less conformal RT. This dilemma can be boiled 
down to the search for the optimal balance between quality 
(e.g. modern high precision treatments) and safety (reliable, 
well proven and understood methods). The priority often 
tends to go towards safety rather than quality since the focus 
from the general public as well as regulatory authorities 
always favours the latter at the expense of the former. As 
medical physicists, however tempting it might be to focus on 
safety only, must take a patient oriented approach and in all 
considerations include the aspect of what will be the most 
beneficial way from a patient’s perspective. Just as a high 
quality cannot be justified to apply is the safety issues are 
not properly handled, safety without quality is of limited 
value. In the search for the ultimate balance between quality 
and safety, the medical physicist is in a key position since no 
other profession has a better understanding of the 
technology, the physics and the interactions between 
different complex systems. A more patient-centred approach 
to accuracy, safety and quality can, however only result from 
a multidisciplinary strategy where different profession work 
together towards the common goal to offer the best possible 
treatment to all patients in need thereof. 
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Purpose or Objective: Current IMRT treatment planning with 
commercial treatment planning systems is a trial-and-error 
process, based on a series of subjective human decisions. So 
the quality of the IMRT treatment plans may not be 
consistent among patients, planners or institutions with 
different experience. Different plan quality assurance (QA) 
tools have been proposed recently, that could flag 
suboptimal plans that may benefit from an additional 
treatment planning effort. However, since conventional 
treatment planning was used to validate these models, the 
inherent accuracy of the existing treatment planning QA 
models is unknown. Therefore we fully automatically 
generated a dataset of Pareto-optimal prostate IMRT plans 
using Erasmus – iCycle, an in-house TPS for fully automated, 
multi-criterial plan generation. This dataset was used to 
assess the prediction accuracy of an overlap volume 
histogram (OVH) based plan QA tool. 
 
Material and Methods: 115 prostate plans were fully 
automatically generated using Erasmus-iCycle. These plans 
were based on a fixed ‘wish-list’ which contains hard 
constraints and objectives in a predefined order of priority. 
An existing OVH model was modified and used to predict 
DVHs for these patients. First, the entire DVH of the rectum, 
bladder and anus of a validation cohort (N=57) were 
predicted, using the plans of an independent training cohort 
(N=58). To investigate the impact on prediction accuracy of 
an enlarged training cohort, the DVHs were also predicted by 
a leave-one-out method. The predicted rectum Dmean, V65, 
and V75, and Dmean of the anus and bladder were compared 
with the achieved values to validate the OVH QA tool. 
 
Results: For rectum, the prediction errors (predicted-
achieved) were small: -0.2±0.9 Gy (mean±1 SD) for Dmean, -
1.0±1.6% for V65, and -0.4±1.1% for V75. 72% and 96% of the 
predicted rectum Dmean had prediction errors within 1 Gy 
and 2 Gy, respectively. For Dmean of anus the prediction 
error was only 0.1±1.6 Gy, whereas for the bladder it was 
much larger: and 4.8±4.1 Gy (see also Fig 1). Increasing the 
training cohort to 114 patients (using leave-one-out) led to 
minor improvement. 
 
Conclusion: A dataset of consistently prioritized Pareto-
optimal prostate IMRT plans was generated. This dataset can 
be used to validate any planning QA model and will be made 
publicly available at the Treatment Planning QA Section of 
http://www.erasmusmc.nl/radiotherapie/research/radiation
oncologymedicalphysicsandimaging/research_projects. It was 
applied here to assess the accuracy of the OVH model. The 
OVH model was highly accurate in predicting rectum and anus 
DVHs. For the bladder large prediction errors were observed, 
which indicates that the OVH has difficulty in capturing the 
interdependence of sparing different OARs. We are currently 
